Bullous Pemphigoid (BP) is an acquired, rare autoimmune skin disorder.&nbsp;It is a subepidermal bullous disease where autoantibodies are directed against the skin&rsquo;s basement membrane zone components.&nbsp;
&nbsp;
Bullous Pemphigoid Epidemiological Segmentation&nbsp;
&nbsp;
The Epidemiological Segmentation of Bullous Pemphigoid in the 7MM from 2018 to 2030 is segmented into:-
&nbsp;
<ul>
<li>Diagnosed Prevalent cases of Bullous Pemphigoid</li>
<li>Gender-specific Diagnosed Prevalent Cases of Bullous Pemphigoid</li>
<li>Age-specific Diagnosed Prevalent Cases of Bullous Pemphigoid</li>
<li>Severity-specific Diagnosed Prevalent Cases of Bullous Pemphigoid</li>
</ul>
&nbsp;
<a style="color: #0047b2; background-color: transparent;" href="https://www.delveinsight.com/report-store/bullous-pemphigoid-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Bullous Pemphigoid Epidemiological Insights</a> Observed in 2020
&nbsp;
<ul>
<li>The total diagnosed prevalent cases of Bullous Pemphigoid in 7MM were found to be 124,517.</li>
<li>The diagnosed prevalent cases of Bullous Pemphigoid in the United Kingdom were observed to be 24,644.</li>
<li>The diagnosed prevalent cases of Bullous Pemphigoid in France were 23,843.</li>
<li>The diagnosed prevalent cases of Bullous Pemphigoid in Germany were found to be 17,626.</li>
<li>The diagnosed prevalent cases of Bullous Pemphigoid in Spain were observed to be 10,920.</li>
<li>The diagnosed prevalent cases of Bullous Pemphigoid Japan were observed to be 8,619.</li>
<li>In the United States, the Age-specific Diagnosed Prevalent cases of Bullous Pemphigoid in males were found to be 11,018, whereas in females, it was observed to be 14,023.</li>
</ul>
&nbsp;
<a style="color: #1155cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/bullous-pemphigoid-market" target="_blank" rel="noopener noreferrer">Bullous Pemphigoid Market</a>
&nbsp;
The market size of Bullous Pemphigoid in the 7MM was found to be USD 151 Million in 2020.
&nbsp;
Bullous Pemphigoid Market Drivers
<ul>
<li>Robust emerging pipeline</li>
<li>Ubiquitous prevalence</li>
<li>Precise diagnostic procedures&nbsp;</li>
</ul>
&nbsp;
Bullous Pemphigoid Market Barriers
<ul>
<li>Complications associated with available therapies</li>
<li>Delayed diagnosis</li>
<li>Polypharmacy</li>
<li>Lack of disease awareness&nbsp;</li>
</ul>
&nbsp;
<a style="color: #0047b2; background-color: transparent;" href="https://www.delveinsight.com/report-store/bullous-pemphigoid-pipeline-insight" target="_blank" rel="noopener noreferrer">Bullous Pemphigoid Emerging Drugs</a>
&nbsp;
The emerging drugs of the Bullous Pemphigoid market are
&nbsp;
<ul>
<li>Dupilumab (Dupixent)</li>
<li>Nomacopan (rVA576, Coversin)</li>
<li>iCo-008 (Bertilimumab)</li>
<li>Avdoralimab (IPH5401)</li>
<li>Fasenra (benralizumab)</li>
<li>AKST4290, and others</li>
</ul>
&nbsp;
Bullous Pemphigoid Key Players
&nbsp;
The key players working in the Bullous Pemphigoid market are&nbsp;
&nbsp;
<ul>
<li>Regeneron Pharmaceuticals</li>
<li>Sanofi</li>
<li>Akari Therapeutics</li>
<li>Immune Pharmaceuticals</li>
<li>iCo Therapeutics</li>
<li>Innate Pharma</li>
<li>AstraZeneca</li>
<li>Alkahest Inc.</li>
<li>Grifols, and others</li>
</ul>

Bullous Pemphigoid Market

Bullous Pemphigoid Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape